SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare secures USFDA’s approval for Bortezomib Injection

27 Aug 2024 Evaluate

Shilpa Medicare has received the approval for its second NDA (505(b)(2)), injectable product - Bortezomib Injection, from USFDA. Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL).

This is the first liquid injection for Bortezomib, approved for both subcutaneous and intravenous administration by the USFDA. The Injection is ‘ready to use’ for subcutaneous administration, offering significant advantages to the health care providers. The Injection has to be diluted for intravenous use. The reference product Velcade is a lyophilized injection which requires reconstitution prior to administration.

Bortezomib Injection, a proteasome inhibitor, contains bortezomib which is an antineoplastic agent. This NDA provides for the use of Bortezomib injection for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.


Shilpa Medicare Share Price

415.00 3.45 (0.84%)
20-Apr-2026 14:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1233.50
Cipla 1232.25
Zydus Lifesciences 937.65
Lupin 2327.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×